Hanifa H.
- Country
- France
- Department
- Oncologie
Research Overview
- Evaluation of 68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-Immunotherapy in Early-Stage High-Risk Triple-Negative Breast Cancer
- Phase III Randomized Study Comparing Chemotherapy Versus Endocrine Therapy with Abemaciclib in ER+ HER2- Breast Cancer with Visceral Metastases
- Evaluation of Adjuvant Pembrolizumab Versus Observation in Early Triple-Negative Breast Cancer with Pathologic Complete Response Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 61 of 186 partner sites.
Specializations
Gynaecological oncology
Clinical research in ovarian cancer, endometrial cancer, cervical cancer, fallopian tube neoplasms, and primary peritoneal cancer, with interest in advanced, recurrent, platinum-resistant, and biomarker-defined disease.
- Advanced and recurrent ovarian malignancies
- Endometrial and uterine cancers
- Cervical and fallopian tube cancers
- Biomarker-selected gynecological tumors
Therapeutic activity includes antibody-drug conjugates, PARP inhibition, immune checkpoint inhibition, and maintenance strategies in difficult-to-treat gynecological cancers.
Breast cancer and hormone receptor-driven disease
Research involvement spans early breast cancer, metastatic breast cancer, triple-negative breast cancer, and HER2-negative or ER-positive disease, including settings defined by recurrence risk and visceral spread.
- ER-positive, HER2-negative breast cancer
- Triple-negative breast cancer
- Early and metastatic breast cancer
- ctDNA-guided endocrine treatment
Therapeutic focus includes endocrine therapy, CDK4/6 inhibition, PI3K-targeted treatment, and HER2-directed therapy in breast malignancies.
Digestive and hepatobiliary cancers
Clinical trial activity covers colorectal cancer, rectal cancer, gastric cancer, oesophagogastric adenocarcinoma, pancreatic adenocarcinoma, biliary cancer, and anal squamous cell carcinoma.
- Colorectal and rectal cancers
- Gastric and oesophagogastric adenocarcinoma
- Pancreatic and biliary malignancies
- Anal and digestive tract cancers
Therapeutic interests include perioperative chemotherapy, radiotherapy, immunotherapy, and biomarker-driven treatment selection in gastrointestinal oncology.
Urologic and genitourinary oncology
Research activity includes bladder cancer, urothelial carcinoma, prostate cancer, and selected advanced solid tumors with genitourinary involvement.
- Non-muscle-invasive and muscle-invasive bladder cancer
- Metastatic urothelial carcinoma
- Prostate cancer
- Advanced genitourinary solid tumors
Therapeutic domains include intravesical therapy, androgen-axis treatment, immune-based therapy, and maintenance approaches for recurrent or high-risk disease.
Selected non-oncology therapeutic interests
Clinical trial involvement also extends to autoimmune disease, infectious complications, gout, fertility treatment, and musculoskeletal disorders.
- Granulomatosis with polyangiitis
- Systemic sclerosis-associated interstitial lung disease
- Complex perianal Crohn’s disease
- Infertility and ovarian stimulation
Therapeutic interest includes immunomodulation, anti-inflammatory treatment, fertility support, and management of chronic inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.